Schrödinger Future Growth
Future criteria checks 1/6
Schrödinger is forecast to grow earnings and revenue by 9.7% and 17.3% per annum respectively. EPS is expected to grow by 10.4% per annum. Return on equity is forecast to be -35% in 3 years.
Key information
9.7%
Earnings growth rate
10.4%
EPS growth rate
Healthcare Services earnings growth | 30.5% |
Revenue growth rate | 17.3% |
Future return on equity | -35.0% |
Analyst coverage | Good |
Last updated | 29 Aug 2024 |
Recent future growth updates
Recent updates
Schrodinger: More Drug Discovery Validation
Aug 06Here's Why We're Watching Schrödinger's (NASDAQ:SDGR) Cash Burn Situation
Aug 05We Think The Compensation For Schrödinger, Inc.'s (NASDAQ:SDGR) CEO Looks About Right
Jun 12Schrödinger: More Pharmaceutical Than Software
May 07Schrödinger, Inc. (NASDAQ:SDGR) Not Flying Under The Radar
May 02Schrödinger, Inc. (NASDAQ:SDGR) Analysts Just Cut Their EPS Forecasts Substantially
Mar 01Schrodinger: Conservative Guidance Sets The Stock Up For A Solid 2024
Mar 01Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?
Feb 28The Price Is Right For Schrödinger, Inc. (NASDAQ:SDGR) Even After Diving 26%
Feb 01Schrödinger, Inc.'s (NASDAQ:SDGR) P/S Still Appears To Be Reasonable
Dec 18Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?
Sep 28Is There An Opportunity With Schrödinger, Inc.'s (NASDAQ:SDGR) 49% Undervaluation?
Jul 01Schrödinger: Q2 Earnings Supports Growth Narrative
Aug 26Schrödinger appoints Dr. Geoffrey Porges as finance chief
Aug 18Sizing Up Schrodinger
Jun 06Schrödinger: Holding The Keys To Discovery
Mar 26Schrodinger: A Long-Term Hold For Biotech Investors With Upside Potential Too
Mar 15Schrödinger: Conviction Remains High, Q4 Report And Guidance Will Be Critical
Jan 06After Its Stock Price Doubled Last Year, Why Schrödinger Is Slumping Now
Nov 24We're Interested To See How Schrödinger (NASDAQ:SDGR) Uses Its Cash Hoard To Grow
Nov 12An Intrinsic Calculation For Schrödinger, Inc. (NASDAQ:SDGR) Suggests It's 38% Undervalued
Oct 05Schrodinger: An Investment In Drug Discovery In Addition To Software Sales
Sep 20Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 302 | -164 | -124 | N/A | 6 |
12/31/2025 | 261 | -176 | -174 | N/A | 11 |
12/31/2024 | 210 | -174 | -217 | N/A | 11 |
6/30/2024 | 201 | -201 | -193 | -180 | N/A |
3/31/2024 | 188 | -143 | -159 | -145 | N/A |
12/31/2023 | 217 | 41 | -150 | -137 | N/A |
9/30/2023 | 199 | 44 | -137 | -124 | N/A |
6/30/2023 | 194 | 66 | -115 | -105 | N/A |
3/31/2023 | 197 | 14 | -121 | -111 | N/A |
12/31/2022 | 181 | -149 | -128 | -120 | N/A |
9/30/2022 | 170 | -153 | -122 | -114 | N/A |
6/30/2022 | 163 | -148 | -102 | -95 | N/A |
3/31/2022 | 154 | -135 | -108 | -99 | N/A |
12/31/2021 | 138 | -100 | -78 | -71 | N/A |
9/30/2021 | 125 | -81 | -14 | -7 | N/A |
6/30/2021 | 121 | -42 | -13 | -9 | N/A |
3/31/2021 | 114 | -11 | 9 | 12 | N/A |
12/31/2020 | 108 | -24 | 14 | 17 | N/A |
9/30/2020 | 101 | -20 | -40 | -38 | N/A |
6/30/2020 | 95 | -35 | -34 | -32 | N/A |
3/31/2020 | 91 | -33 | -29 | -27 | N/A |
12/31/2019 | 86 | -25 | -28 | -26 | N/A |
9/30/2019 | 77 | -24 | -26 | -24 | N/A |
6/30/2019 | 70 | -24 | -29 | -25 | N/A |
3/31/2019 | 69 | -29 | -29 | -25 | N/A |
12/31/2018 | 67 | -28 | -29 | -24 | N/A |
12/31/2017 | 56 | -17 | N/A | -15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SDGR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SDGR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SDGR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SDGR's revenue (17.3% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: SDGR's revenue (17.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SDGR is forecast to be unprofitable in 3 years.